Cargando...
Novel antidotes for target specific oral anticoagulants
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing cl...
Guardado en:
| Publicado en: | Exp Hematol Oncol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570637/ https://ncbi.nlm.nih.gov/pubmed/26380149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0020-3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|